Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Microbially Produced Imidazole Propionate Is Associated With Heart Failure and Mortality

Molinaro, Antonio ; Nemet, Ina ; Bel Lassen, Pierre ; Chakaroun, Rima ; Nielsen, Trine ; Aron-Wisnewsky, Judith ; Bergh, Per Olof ; Li, Lin ; Henricsson, Marcus and Køber, Lars , et al. (2023) In JACC: Heart Failure 11(7). p.810-821
Abstract

Background: Over the past years, it has become clear that the microbial ecosystem in the gut has a profound capacity to interact with the host through the production of a wide range of bioactive metabolites. The microbially produced metabolite imidazole propionate (ImP) is clinically and mechanistically linked with insulin resistance and type 2 diabetes, but it is unclear how ImP is associated with heart failure. Objectives: The authors aimed to explore whether ImP is associated with heart failure and mortality. Methods: ImP serum measurements in 2 large and independent clinical cohorts of patients (European [n = 1,985] and North American [n = 2,155]) with a range of severity of cardiovascular disease including heart failure. Univariate... (More)

Background: Over the past years, it has become clear that the microbial ecosystem in the gut has a profound capacity to interact with the host through the production of a wide range of bioactive metabolites. The microbially produced metabolite imidazole propionate (ImP) is clinically and mechanistically linked with insulin resistance and type 2 diabetes, but it is unclear how ImP is associated with heart failure. Objectives: The authors aimed to explore whether ImP is associated with heart failure and mortality. Methods: ImP serum measurements in 2 large and independent clinical cohorts of patients (European [n = 1,985] and North American [n = 2,155]) with a range of severity of cardiovascular disease including heart failure. Univariate and multivariate Cox regression analyses were performed to delineate the impact of ImP on 5-year mortality in the North American cohort, independent of other covariates. Results: ImP is independently associated with reduced ejection fraction and heart failure in both cohorts, even after adjusting for traditional risk factors. Elevated ImP was a significant independent predictor of 5-year mortality (for the highest quartile, adjusted HR: 1.85 [95% CI: 1.20-2.88]; P < 0.01). Conclusions: The gut microbial metabolite ImP is increased in individuals with heart failure and is a predictor of overall survival.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
heart failure, histidine, imidazole propionate, microbiota
in
JACC: Heart Failure
volume
11
issue
7
pages
12 pages
publisher
Elsevier
external identifiers
  • pmid:37115134
  • scopus:85160840012
ISSN
2213-1779
DOI
10.1016/j.jchf.2023.03.008
language
English
LU publication?
yes
id
8edef929-b462-4113-850f-dd3af534db53
date added to LUP
2023-12-20 15:18:34
date last changed
2024-04-19 00:51:23
@article{8edef929-b462-4113-850f-dd3af534db53,
  abstract     = {{<p>Background: Over the past years, it has become clear that the microbial ecosystem in the gut has a profound capacity to interact with the host through the production of a wide range of bioactive metabolites. The microbially produced metabolite imidazole propionate (ImP) is clinically and mechanistically linked with insulin resistance and type 2 diabetes, but it is unclear how ImP is associated with heart failure. Objectives: The authors aimed to explore whether ImP is associated with heart failure and mortality. Methods: ImP serum measurements in 2 large and independent clinical cohorts of patients (European [n = 1,985] and North American [n = 2,155]) with a range of severity of cardiovascular disease including heart failure. Univariate and multivariate Cox regression analyses were performed to delineate the impact of ImP on 5-year mortality in the North American cohort, independent of other covariates. Results: ImP is independently associated with reduced ejection fraction and heart failure in both cohorts, even after adjusting for traditional risk factors. Elevated ImP was a significant independent predictor of 5-year mortality (for the highest quartile, adjusted HR: 1.85 [95% CI: 1.20-2.88]; P &lt; 0.01). Conclusions: The gut microbial metabolite ImP is increased in individuals with heart failure and is a predictor of overall survival.</p>}},
  author       = {{Molinaro, Antonio and Nemet, Ina and Bel Lassen, Pierre and Chakaroun, Rima and Nielsen, Trine and Aron-Wisnewsky, Judith and Bergh, Per Olof and Li, Lin and Henricsson, Marcus and Køber, Lars and Isnard, Richard and Helft, Gerard and Stumvoll, Michael and Pedersen, Oluf and Smith, J. Gustav and Tang, W. H.Wilson and Clément, Karine and Hazen, Stanley L. and Bäckhed, Fredrik}},
  issn         = {{2213-1779}},
  keywords     = {{heart failure; histidine; imidazole propionate; microbiota}},
  language     = {{eng}},
  number       = {{7}},
  pages        = {{810--821}},
  publisher    = {{Elsevier}},
  series       = {{JACC: Heart Failure}},
  title        = {{Microbially Produced Imidazole Propionate Is Associated With Heart Failure and Mortality}},
  url          = {{http://dx.doi.org/10.1016/j.jchf.2023.03.008}},
  doi          = {{10.1016/j.jchf.2023.03.008}},
  volume       = {{11}},
  year         = {{2023}},
}